TYSABRI & AVONEX: Interview with Biogen Chief executive James C. Mullen - The Boston Globe
For Biogen Idec Inc., the return of the multiple sclerosis drug Tysabri to the market and continued sales growth for its cash cow, Avonex, were the highlights of 2006.

Q How is Biogen Idec doing?
A In spite of the trials and tribulations of 2005 (when sales of Tysabri were suspended), the actual financial results were fine. In 2006, we continue to accelerate on that. Tysabri has made its way back to the market. People are still obsessed with how many prescriptions we have today. That will take care of itself over time. It's on the market in the US and Europe.

Q What percentage of revenue and profits come from Avonex?
A It's probably in the range of a little over 50 percent on both revenues and profits. Rituxan and Avonex generate the bulk of revenues and profits.

Q Are prescriptions of Tysabri, which Biogen markets with Elan Corp., robust enough to become a significant financial contributor?
A Tysabri will become a significant contributor. It won't be this year because it's just getting going. Unless it hits a major pothole like it hit before, it will probably eclipse Avonex over time. People have generally lost sight of Tysabri outside of multiple sclerosis.
MORE- The Boston Globe